Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150121 | 0.87 | CA1 (0.51) | CA1CA2XDHSLC22A12ALDH1A1 | |
| SCHEMBL7673409 | 0.85 | CA1 (0.45) | CA1CA2XDHSLC22A12ALDH1A1 | |
| SCHEMBL756422 | 0.85 | XDH (0.62) | CA1CA2XDHSLC22A12ALDH1A1 | |
| SCHEMBL26337729 | 0.83 | KDM4E (0.53) | CA1CA2XDHSLC22A12ALDH1A1 | |
| SCHEMBL7671173 | 0.82 | CA1 (0.54) | CA1CA2XDHSLC22A12ALDH1A1 | |
| SCHEMBL2483533 | 0.80 | KDM4E (0.52) | CA1CA2XDHSLC22A12ALDH1A1 | |
| SCHEMBL2154152 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HPGDMAPTKDM4EMEN1 | |
| SCHEMBL3914053 | 0.75 | CDC25B (0.60) | ALDH1A1HPGDMAPTKDM4EMEN1 | |
| SCHEMBL21815744 | 0.74 | MEN1 (0.50) | ALDH1A1HPGDMAPTHTTKDM4E | |
| SCHEMBL7304752 | 0.74 | CA1 (0.61) | CA1CA2XDHSLC22A12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954678-B1 | NOVEL NK1 AND NK2 ANTAGONISTS | ABBOTT PRODUCTS GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-1954678-B1 | NOVEL NK1 AND NK2 ANTAGONISTS | ABBOTT PRODUCTS GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592344-B2 | NK1 and NK2-antagonists and compositions and methods of using the same | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| EP-1549615-B1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1954678-A1 | NOVEL NK1 AND NK2 ANTAGONISTS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20040106610-A1 | Compounds | BERNSTEIN PETER ROBERT (US) | 2004-06-03 | — | — | US | disclosed |
| WO-2004020411-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
| US-6586432-B2 | Peptide neurotransmitter suppressors such as N-((-2-(3,4-dichlorophenyl)-4-morholino)butyl)-N-methyl-2-methoxy-3-cyano-1 -naphthamide, used for prophylaxis of arthritis, pain, alzheimer's disease, schizophrenia, edema, rhinitis or asthma | ASTRAZENELA AB (SE) | 2003-07-01 | — | — | US | disclosed |
| US-20030092713-A1 | Neurokinin-1 receptor antagonists | BERNSTEIN PETER ROBERT (US) | 2003-05-15 | — | — | US | disclosed |
| US-6476077-B1 | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | ASTRAZENECA AB (SE) | 2002-11-05 | — | — | US | disclosed |
| US-6365602-B1 | FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS | ASTRA ZENECA AB (SE) | 2002-04-02 | — | — | US | disclosed |
| EP-1169302-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| EP-1097137-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000059873-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000002859-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106610-A1 | Compounds | NR2C2, NR0B2, NR5A2 | CA1 3229/4885CA2 2210/4885XDH 3863/4885 |
| US-20030092713-A1 | Neurokinin-1 receptor antagonists | NTSR2, NTSR1, CRHR2 | CA1 1172/4885CA2 627/4885XDH 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.